LT3496743T - Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais - Google Patents

Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais

Info

Publication number
LT3496743T
LT3496743T LTEPPCT/US2017/050816T LTUS2017050816T LT3496743T LT 3496743 T LT3496743 T LT 3496743T LT US2017050816 T LTUS2017050816 T LT US2017050816T LT 3496743 T LT3496743 T LT 3496743T
Authority
LT
Lithuania
Prior art keywords
immunooncological
preparations
cancer
compositions
treatment
Prior art date
Application number
LTEPPCT/US2017/050816T
Other languages
English (en)
Inventor
David Lowe
Scott Rowlinson
Susan ALTERS
Giulia AGNELLO
Original Assignee
Aerase, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerase, Inc. filed Critical Aerase, Inc.
Publication of LT3496743T publication Critical patent/LT3496743T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/US2017/050816T 2016-08-08 2017-09-08 Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais LT3496743T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662372092P 2016-08-08 2016-08-08
US201762524286P 2017-06-23 2017-06-23
PCT/US2017/050816 WO2018032020A1 (en) 2016-08-08 2017-09-08 Compositions and methods for treating cancer with arginine depletion and immuno oncology agents

Publications (1)

Publication Number Publication Date
LT3496743T true LT3496743T (lt) 2022-04-11

Family

ID=61163268

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/050816T LT3496743T (lt) 2016-08-08 2017-09-08 Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais

Country Status (19)

Country Link
US (2) US10729752B2 (lt)
EP (1) EP3496743B1 (lt)
AU (1) AU2017310541B2 (lt)
BR (1) BR112019002458A2 (lt)
CY (1) CY1125158T1 (lt)
DK (1) DK3496743T3 (lt)
ES (1) ES2909556T3 (lt)
GB (1) GB2568000A (lt)
HR (1) HRP20220406T1 (lt)
HU (1) HUE057901T2 (lt)
IL (1) IL264535B (lt)
LT (1) LT3496743T (lt)
PL (1) PL3496743T3 (lt)
PT (1) PT3496743T (lt)
RS (1) RS63075B1 (lt)
RU (1) RU2771313C2 (lt)
SI (1) SI3496743T1 (lt)
SM (1) SMT202200157T1 (lt)
WO (1) WO2018032020A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3496743B1 (en) 2016-08-08 2022-02-09 AERase, Inc. Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US12508306B2 (en) 2018-04-25 2025-12-30 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
WO2020063668A1 (zh) * 2018-09-25 2020-04-02 信达生物制药(苏州)有限公司 包含抗ox40抗体的制剂、其制备方法及其用途
CA3116736A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
US20210189371A1 (en) 2019-08-30 2021-06-24 Aeglea Biotherapeutics, Inc. Methods For Production Of Human Recombinant Arginase 1 And Uses Thereof
WO2022195629A1 (en) * 2021-03-18 2022-09-22 National Institute Of Pharmaceutical Education And Research (Niper) Engineered arginase constructs, method of generation and uses thereof
CN118497178A (zh) * 2023-02-15 2024-08-16 重庆派金生物科技有限公司 精氨酸脱亚胺酶突变体、共价二聚体及其偶联物和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02117383A (ja) 1988-10-26 1990-05-01 Tosoh Corp ヒトアルギナーゼの製造方法
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
AU2003216109A1 (en) 2002-01-25 2003-09-02 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
CN1745847A (zh) 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
SI3778885T1 (sl) 2008-10-31 2023-07-31 Aerase, Inc. Sestavki inženirskih humanih arginaz in metode za zdravljenje raka
JP2012531893A (ja) 2009-06-29 2012-12-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム アルギナーゼ製剤および方法
WO2012061015A2 (en) * 2010-11-03 2012-05-10 Scott & White Healthcare L-citrulline supplementation during arginine depletion therapy with arginase
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
DE212015000061U1 (de) 2014-02-11 2017-09-03 The Regents Of The University Of Colorado, A Body Corporate CRISPR-ermöglichtes Multiplex Genom Engineering
CA2944903A1 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP2982758A1 (en) 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
HUE043847T2 (hu) * 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
AU2015343337A1 (en) * 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
US20180271960A1 (en) * 2015-09-21 2018-09-27 Bio-Cancer Treatment International Ltd. Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
EP3496743B1 (en) 2016-08-08 2022-02-09 AERase, Inc. Compositions and methods for treating cancer with arginine depletion and immuno oncology agents

Also Published As

Publication number Publication date
RU2019106501A3 (lt) 2021-01-15
PT3496743T (pt) 2022-03-30
HRP20220406T1 (hr) 2022-05-27
IL264535B (en) 2022-01-01
GB2568000A (en) 2019-05-01
GB201903065D0 (en) 2019-04-24
AU2017310541A1 (en) 2019-03-07
EP3496743B1 (en) 2022-02-09
AU2017310541B2 (en) 2024-06-13
US20200360493A1 (en) 2020-11-19
PL3496743T3 (pl) 2022-05-30
ES2909556T3 (es) 2022-05-09
BR112019002458A2 (pt) 2019-05-14
EP3496743A1 (en) 2019-06-19
DK3496743T3 (da) 2022-04-04
RU2771313C2 (ru) 2022-04-29
WO2018032020A1 (en) 2018-02-15
RS63075B1 (sr) 2022-04-29
CY1125158T1 (el) 2024-02-16
US20180177853A1 (en) 2018-06-28
RU2019106501A (ru) 2020-09-14
IL264535A (en) 2019-02-28
EP3496743A4 (en) 2020-03-18
SI3496743T1 (sl) 2022-08-31
SMT202200157T1 (it) 2022-05-12
HUE057901T2 (hu) 2022-06-28
US10729752B2 (en) 2020-08-04

Similar Documents

Publication Publication Date Title
IL258955A (en) Compositions and methods for treatment of cancer
IL269150A (en) Compositions and methods for treating cancer
IL263224A (en) Methods and compositions for treating cancers
IL268814A (en) Compositions and methods for treatment of cancer
IL253243A0 (en) Combined preparations for the treatment of cancer or infection
IL248193B (en) Compositions for use in treating nafld and nash
LT3496743T (lt) Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais
LT3496739T (lt) Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti
LT3331900T (lt) Peptidai ir peptidų derinys, skirti naudoti imunoterapijai gydant prostatos vėžį ir kitų rūšių vėžį
HUE059694T2 (hu) Készítmény rák kezelésére
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
IL268872A (en) Methods and compositions for treating cancers using antisense
ZA201900960B (en) Methods and compositions for the treatment of cancer
IL269157A (en) Compositions and methods for treating cancer
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL257274B (en) Compositions and methods for treating cancers associated with etbr activation
IL261920A (en) Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
IL246607B (en) Improved cell compositions and methods for cancer therapy
IL263793A (en) Compounds and preparations for the treatment of cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL280587B (en) Fluorocitidine derivatives and their preparations for use in cancer treatment
EP3185910A4 (en) Methods and compositions for the treatment of cancer
IL251345B (en) Compositions for use in the treatment of peri-implantitis
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도